Agenus (AGEN), a clinical-stage, small-cap, pharmaceutical biotechnology company, has seen its stock price slump since January 2019. On June 6, 2019, Agenus closed at $2.66, down 31% since it peaked at its 52-week high of $3.88 in January.
I believe the likely explanation for the slump is a lack of news, combined with the long timelines for getting cancer therapies from conception to commercial sales. However, there have also been attempts to knock clinical stage companies into bankruptcy by short raiders, and Agenus may be one of their targets. I will go into